Background: Circulating microRNAs (miRNAs) are attracting major interest as potential non-invasive biomarkers for colorectal cancer (CRC). This study aimed to identify a novel serum miRNA biomarker for the early detection and/or evaluating prognosis of CRC patients.
and matched primary CRC tissue have been undertaken. Such studies are essential because increased expression of circulating miRNAs would be indicative of miRNAs secreted from tumor tissue, raising the overall diagnostic specificity of the biomarker.
In this study, we carried out comprehensive miRNA microarray analyses in serum from healthy control subjects, and patients with colorectal adenomas and cancers to observe serum miRNA expression profiles differed significantly between controls and adenoma or CRC. In addition, we focused on the selected candidate miRNA as a potential circulating biomarker for the early detection and prognosis of CRC, considering that the expression pattern of this miRNA in serum mirrored that in the neoplastic tissues.
materials and methods

patients, study design, and clinical specimens
This study included analysis of 692 serum and tissue specimens that were obtained from healthy volunteers and consecutively enrolled patients with colorectal adenomas or cancers at the Mie University Hospital, Japan, between January 2004 and December 2011. Serum and tissue samples were stored at −80°C until use. Additional details on patients, study design, and clinical specimens are provided in supplementary Materials and Methods, available at Annals of Oncology online. The study was approved by the institutional review board of Mie University Hospital, Japan (No. 2600). All participants provided a written informed consent and indicated willingness to donate their blood and tissue samples for research.
miRNA expression profiling using microarrays
The custom miRNA expression microarray was utilized for expression profiling in serum samples from CRC patients (n = 3), colorectal adenoma patients (n = 3), and healthy controls (n = 3) (for details, refer to supplementary Materials and Methods, available at Annals of Oncology online).
cell lines and culture conditions
Human CRC cell lines Caco2, DLD1, HT29, LoVo, and SW480 were obtained from the Cell Resource Center of Biomedical Research, Institute of Development, Aging and Cancer (Tohoku University, Sendai, Japan). Cell culture conditions are described in supplementary Materials and Methods, available at Annals of Oncology online.
total RNA isolation and quantitative reverse transcription-polymerase chain reaction
MiRNA extraction from serum and cell culture media samples was carried out using the miRNeasy Mini Kit (Qiagen, Valencia, CA; for details, refer to supplementary Materials and Methods, available at Annals of Oncology online). MiRNA extraction from formalin-fixed and paraffin-embedded (FFPE) tissue samples and CRC cell lines was carried out with miRNeasy FFPE Kit (Qiagen) and miRNeasy Mini Kit according to the manufacturer's protocol, respectively. TaqMan miRNA quantitative reverse transcriptionpolymerase chain reaction (qRT-PCR) (Applied Biosystems, Foster City, CA) was used to detect and quantify miRNA expression using the 2 -ΔCt method (for details, refer to supplementary Materials and Methods, available at Annals of Oncology online).
proliferation, wound healing, and invasion assays Proliferation, wound healing, and invasion assays were carried out to assess the function of miR-1290. Additional experimental details on these assays are provided in supplementary Materials and Methods, available at Annals of Oncology online.
statistical analyses
All statistical analyses were carried out using JMP version 10 (SAS Institute, Cary, NC). All P values were two-sided, and those <0.05 were considered statistically significant. Details are provided in supplementary Materials and Methods, available at Annals of Oncology online.
results serum miRNA microarray analysis revealed miR-1290 as the most promising candidate diagnostic biomarker in CRC Thirty-four miRNAs in serum showed a potential to separate those two clinical groups (group of healthy subjects and patients with neoplasia including with adenoma and CRC) with a P value of <0.01 by Student's t-test (supplementary Figure S1 and Table S1 , available at Annals of Oncology online). Among these miRNAs, serum miR-1290 expression showed highest differential fold-change between healthy controls and patients with colorectal neoplasia (fold change = 4.48 supplementary Table S1 , available at Annals of Oncology online). Therefore, we selected miR-1290 as the candidate miRNA and it appeared to be the most promising marker for early diagnostic of colorectal neoplasia.
human CRC cell lines express miR-1290, and also secrete it into the culture medium
We investigated the cellular expression of miR-1290 by TaqMan-based qRT-PCR assays in human CRC cell lines (supplementary Figure S2A , available at Annals of Oncology online). Of the five CRC cell lines, LoVo and HT29 cells showed higher expression levels of miR-1290 than the other cells. Next, we confirmed the secretory potential of miR-1290 into the culture media by using LoVo and SW480 cells. We observed that miR-1290 expression in the culture media from both cell lines increased with time and with increasing numbers of CRC cells (2-8 × 10 5 cells/well) (supplementary Figure S2B and C, available at Annals of Oncology online).
high levels of tissue and serum miR-1290 expression confirmed in the training step in clinical specimens from CRC patients
In the training step, tissue miR-1290 expression levels were examined in a small set of CRC (n = 12), the adjacent normal mucosa (n = 12), and colorectal adenomas (n = 12) (supplementary Figure  S3A , available at Annals of Oncology online). MiR-1290 expression levels were significantly elevated in CRC and colorectal adenoma tissues compared with normal mucosa (CRC: P < 0.0001; adenoma: P = 0.0002). Next, we determined the feasibility of detecting the expression of circulating miR-1290 in 36 serum samples from CRC patients (n = 12), colorectal adenoma patients (n = 12), and healthy control subjects (n = 12; supplementary Figure S3B , available at Annals of Oncology online). MiR-1290 expression in the sera of CRC patients showed statistically significantly higher levels compared with those from normal subjects and adenoma patients (P < 0.0001 and 0.0027, respectively). Receiver operating characteristic (ROC) analyses showed that serum miR-1290 levels could discriminate CRC patients from control subjects, with an area under the curve (AUC) value of 1.000 (sensitivity: 100%, specificity: 100%, cut-off value: 0.0000254) (supplementary Figure S3C , available at Annals of Oncology online). Furthermore, serum miR-1290 levels could differentiate colorectal adenoma patients from control subjects with an AUC value of 0.722 (sensitivity: 50.0%, specificity: 100%, cut-off value: 0.0000238) (supplementary Figure S3D , available at Annals of Oncology online).
over-expression of tissue and serum miR-1290 expression was validated in an independent cohort of CRC patients
The characteristics of participants (n = 503) in the validation phase are summarized in supplementary Table S2 , available at Annals of Oncology online. There were no statistically significant differences in age and gender between healthy subjects, patients with colorectal adenomas, CRC patients for tissue and serum analyses, respectively.
A total of 324 serum samples, including those from CRC patients (n = 211), colorectal adenoma patients (n = 56), and healthy controls (n = 57), were examined to evaluate the diagnostic potential of serum miR-1290. Serum miR-1290 levels showed a significant stepwise increase in patients with colorectal adenomas (P < 0.0001) and CRC (P < 0.0001) compared with healthy control subjects ( Figure 1A) . Moreover, the gradual increase in serum miR-1290 levels was clearly discernible based upon TNM stage, with significantly higher levels in stage IV patients compared with stage I-III patients (P < 0.001; Figure 1A ). As illustrated in Table 1 , serum miR-1290 levels were significantly higher in CRC patients with larger tumor size (P = 0.0015), serosal invasion (P = 0.033), lymphatic and venous invasion (P = 0.0098 and 0.0042, respectively) and metastasis to several distant organs (lymph node: P = 0.018; liver: P < 0.0001; peritoneum: P < 0.0001, respectively).
Next, our ROC analyses showed that serum miR-1290 levels could discriminate CRC patients from control subjects, with an AUC value of 0.830 (sensitivity: 70.1%, specificity: 91.2%, cutoff value: 0.0000182) ( Figure 1B) . Furthermore, from a screening perspective, serum miR-1290 levels could differentiate colorectal adenoma patients from control subjects, with an AUC value of 0.718 (sensitivity: 46.4%, specificity: 91.2%, cut-off value: 0.0000187) ( Figure 1C) . the tissue and serum miR-1290 expression levels correlated in CRC patients MiR-1290 expression in adenoma and CRC tissues was significantly increased compared with normal colonic mucosa, respectively (adenoma: P < 0.0001; CRC: P < 0.0001), and miR-1290 levels in CRC associated with clinical stage (stage I versus IV: P = 0.0032; supplementary Figure S4A , available at Annals of Oncology online). Table 1 shows significant associations between high miR-1290 expression in CRC and large tumor size (P = 0.0023), serosal invasion (P = 0.027), lymphatic (P = 0.027) and venous invasion (P = 0.021), lymph node metastasis (P = 0.016), and liver metastasis (P = 0.012). Collectively, the same pattern of gradual increase in miR-1290 expression levels was observed in serum samples and tissue from CRC patients.
We further examined the relationship between miR-1290 expression levels in primary CRC tissues and matched serum using an independent cohort (n = 91). Interestingly, we observed a statistically significant positive correlation of miR-1290 expression levels between primary CRC tissues and matched serum samples (ρ = 0.482; P < 0.0001; supplementary Figure S4B , available at Annals of Oncology online).
Subsequently, we analyzed paired pre-and post-operative serum samples in a subset of 72 CRC patients who underwent surgical resection of their neoplasms. It was very interesting that serum miR-1290 levels significantly diminished after surgical resection of the primary tumor in the same patients' serum specimens (P < 0.0001; supplementary Figure S4C , available at Annals of Oncology online). Moreover, when analyzed only in the patients group that received potentially curative operation, post-operative reductions in serum miR-1290 levels were significantly dramatic (P < 0.0001; supplementary Figure S4D , available at Annals of Oncology online). On the other hand, less significant differences were observed in the serum miR-1290 levels of the patients with non-curative resections (P = 0.012; supplementary Figure S4E , available at Annals of Oncology online).
the tissue and serum miR-1290 expression serves as a prognostic biomarker in CRC
The Kaplan-Meier survival analysis demonstrated that patients with higher miR-1290 expression in CRC tissues (>0.047) showed significantly poorer overall survival (P = 0.0082; Figure 1D ). Furthermore, higher serum miR-1290 levels (>0.000039) also showed significantly worse overall survival (P < 0.0001; Figure 1E ). In addition, elevated serum miR-1290 levels (>0.000039) were significantly associated with poor overall survival in stage II and III CRC patients (P = 0.039; Figure 1F ).
Moreover, in CRC tissue sample cohort, univariate Cox proportional hazards regression analyses revealed that poor overall survival in CRC patients was associated with high miR-1290 expression in CRC tissue (P = 0.023), large tumor size (P = 0.0065), lymphatic invasion (P = 0.0004), venous invasion (P = 0.0035), high T stage (T3/4; P < 0.0001), lymph node metastasis (P = 0.0002), distant metastasis (P < 0.0001), and high carcinoembryonic antigen levels (CEA ≥5 ng/ml; P < 0.0001) ( Table 2 ). However, high miR-1290 expression in CRC tissue did not serve as an independent prognostic marker for overall survival in multivariate analysis. On the other hand, in CRC serum sample cohort, univariate analyses revealed that poor overall survival in CRC patients was associated with high serum miR-1290 levels (P = 0.0001), poorly differentiated tumor (P < 0.0001), lymphatic invasion (P = 0.030), venous invasion (P = 0.0074), high T stage (P < 0.0001), lymph node metastasis (P = 0.0002), distant metastasis (P < 0.0001), and high CEA levels (P = 0.0003) ( Table 2 ). More importantly, multivariate analysis revealed that high serum miR-1290 levels, but not high levels of tissue miR-1290 or high CEA levels, served as an independent prognostic marker for predicting poor overall survival in CRC patients [hazard ratio (HR) = 4.51; 95% confidence interval (CI) = 1.23-23.69; P = 0.0096; Table 2 ].
serum miR-1290 is a tumor recurrence predictive biomarker in CRC higher levels of serum miR-1290 (>0.000039) had significantly shorter disease-free survival than those with lower expression of this miRNA in patients with stage I-III (P = 0.05; Figure 1G ). To determine whether serum miR-1290 expression was an independent risk factor for early recurrence, the Cox's proportional hazard regression model was employed (supplementary Table S3 , available at Annals of Oncology online). In univariate analysis, high levels of miR-1290 in serum (P = 0.035), high levels of CEA (P = 0.05), high pathological T stage (T3/4; P = 0.026), lymph node metastasis (P = 0.0081), and poor differentiation (P = 0.032) were significantly associated with poor disease-free survival. On the contrary, multivariate analysis showed that high serum miR-1290 expression was an independent predictor of tumor recurrence after curative surgery (HR = 3.92; 95% CI = 1.11-25.14; P = 0.032; supplementary Table S3 , available at Annals of Oncology online).
In addition, we assessed the biomarker potential of serum miR-1290 as a predictor of relapse in the subset of patients that we collected post-surgery (day 7 post-surgery). ROC analyses showed that the serum miR-1290 levels were able to discriminate stage I-III CRC patients with recurrence from those without recurrence, with an AUC value of 0.681 (supplementary Figure S4F , available at Annals of Oncology online). Using a cut-off value of 0.000019, the sensitivity, specificity, positive predictive value, and negative predictive value for identifying stage I-III CRC patient with recurrence were 58.3%, 79.4%, 31.6%, 
miR-1290 contributes to the proliferation, migration, and invasion in CRC cells
We analyzed various cellular functions such as proliferation, migration, and invasion. In the proliferation assay, knockdown of miR-1290 revealed statistically significantly inhibition of CRC cell proliferation after hsa-miR-1290 inhibitor transfection compared with the control cells (*P < 0.05; **P < 0.01; supplementary Figure S5A and B, available at Annals of Oncology online).
Next, hsa-miR-1290 inhibitor-transfected cells showed significantly decreased migratory and invasive ability compared with cells transfected with miRNA inhibitor negative control (*P < 0.05; **P < 0.01; supplementary Figure S5F , available at Annals of Oncology online).
discussion
In this study, we first carried out comprehensive microarrays to analyze serum miRNA expression profiles using serum samples from CRC patients, colorectal adenoma patients, and healthy normal subjects during a screening step. Based on this array result, we identified miR-1290 to be expressed at significantly higher levels in the serum of CRC patients and colorectal adenoma patients compared with healthy controls. In vitro analysis revealed that miR-1290 levels in culture media of CRC cell lines increased in a time-and cell number-dependent manner, which demonstrated the secretory nature of this miRNA for development as a non-invasive biomarker for the detection of colorectal neoplasia. Secondly, we observed increased miR-1290 expression levels in an independent training set of serum and tissue samples from CRC patients, colorectal adenoma patients, and normal control subjects, which verified the specificity of miR-1290 expression in the circulation. Thirdly, we successfully validated the up-regulation of miR-1290 expression using an independent large cohort of CRC tissue and serum samples. Previous studies have reported that miR-1290 was highly expressed in several cancers, including CRC [10] . Although the biological significance of miR-1290 in cancer remains poorly understood, there are several evidences indicating that miR-1290 promotes epithelial-mesenchymal transition (EMT) and subsequently maintains cancer stem cell population in tumors. Overexpression of miR-1290 was demonstrated as one of the causes of multi-nucleated cell formation which leads to cellular reprogramming in colon cancer [10] . Furthermore, Sun et al. [11] demonstrated that the expression of miR-1290 was up-regulated in CD133-positive cancer cells, and suppression of miR-1290 significantly inhibited the proliferation, clonogenicity, invasion, and migration of CD133-positive cancer cells by targeting fyn-related Src family tyrosine kinase in non-small-cell lung cancer (NSCLC). In addition, it has been reported that miR-1290 up-regulates stemness and EMT-associated markers, and promotes proliferation, sphere-formation, colony formation, and invasion in NSCLC [12] . Although the current study did not show the association between miR-1290 and EMT or cancer stemness, our data strongly suggest that miR-1290 is involved in promoting metastatic potential of CRC cells through enhancing cell proliferation, migration, and invasion and these results are consistent with previous reports [13] [14] [15] . Accordingly, several downstream target genes of miR-1290 has been identified include tumor suppressor genes such as Forkhead box protein A1 [13] , N-acetyltransferase 1 [14] , and Suppressor of cancer cell invasion [15] .
Although our observation that miR-1290 expression levels were significantly increased in CRC tissues compared with adjacent normal mucosa, which is consistent with previous report [10] , we for the first time investigated the clinicopathological significance of miR-1290 expression in primary CRC tissues and clinicopathological parameters demonstrating that miR-1290 promotes tumor progression in CRC. Furthermore, we showed that the patients with higher miR-1290 expression in CRC tissues had significantly poorer overall survival compared with those with low miR-1290 expression. We then confirmed our findings using a set of CRC data available on The Cancer Genome Atlas (TCGA). Furthermore, to validate whether miR-1290 expression in CRC associate with prognosis of CRC patients, we analyzed the association between miR-1290 and the prognosis of CRC patients using CRC data available on The Cancer Genome Atlas (TCGA). Interestingly, high miR-1290 expression in CRC had significantly poorer prognosis than those with low miR-1290 expression (data not shown), which is consistent with our clinical data. Collectively, these data indicate that the expression of miR-1290 in CRC could be used as a potential surrogate marker for aggressiveness and invasiveness for CRC and may have contributed to poorer prognosis. Likewise, high expression levels of miR-1290 in serum samples of CRC patients are associated with large tumor size, vessel invasion, high T Stage, lymph node metastasis, liver metastasis, peritoneal metastasis, distant metastasis, and advanced TNM stage. Furthermore, our study showed another interesting finding that there was a significant correlation between miR-1290 expression in primary CRC tissues and those in sera. The fact that miR-1290 levels in serum of post-operative patients significantly decreased compared with those of preoperative CRC patients strongly support the hypothesis that the circulating miR-1290 in serum of CRC patients is likely produced and secreted by the CRC cells. This is the first study to demonstrate that serum miR-1290 serves as a potential biomarker for the early detection of colorectal neoplasia. This is supported by the observation for an AUC value of 0.830 derived from comparisons between CRC patients and healthy control subjects. More important aspects of the screening for colorectal neoplasms, serum miR-1290 expression levels demonstrated AUC values of 0.718 for discriminating patients with colorectal adenomatous polyps from healthy controls in a non-invasive manner. However, despite circulating miR-1290 was able to discriminate adenoma patients in both the training and validation sets (50.0% and 46.4% sensitivity, respectively), circulating miR-1290 remains inadequate on its own as a clinically viable biomarker for early detection of colorectal neoplasia. Nonetheless, our investigation highlights that serum miR-1290 expression can be utilized not only as a potential non-invasive biomarker for CRC diagnosis but also for the identification of clinically meaningful adenomas which are the target lesion for any CRC screening strategy.
Furthermore, another interesting finding in this study is that serum miR-1290 expression also serves as a promising prognostic biomarker for CRC patients. Although Huang et al. [16] have shown that plasma exosomal miR-1290 was a promising biomarker for castration-resistant prostate cancer patients, this is the first study demonstrating the potential role of miR-1290 as a prognostic biomarker in CRC. Our findings that high levels of tissue and serum miR-1290 expression levels showed a poor prognosis in CRC patients is an important step toward the identification of prognostic biomarkers for this disease. More interestingly, the multivariate analyses of Cox proportional hazards regression model demonstrated that high expression of serum miR-1290 was an independent prognostic variable, whereas the prognostic values of CEA levels and miR-1290 expression in the tumor tissues were statistically compromised by other clinical factors.
Our key findings are of particular interest because these highlight that overexpression of miR-1290 in serum as well as lymph node metastasis indicates that this miRNA could be used as an independent predictor of early recurrence in CRC with a curative intent. In addition, data derived from serum miR-1290 levels at 7 days postsurgery (POD7) suggest that miR-1290 could predict the curative CRC patients who will suffer from recurrence. Furthermore, adjuvant chemotherapy did not contribute to reduction in recurrence in low serum miR-1290 group on POD7. In contrast, recurrence rate of curative CRC patients with adjuvant chemotherapy was significantly lower than those without chemotherapy in the high serum miR-1290 group on POD7. Collectively, these results suggest that serum miR-1290 is capable of detecting micro-residual tumors as the metastatic deposits.
Recently, a study demonstrated that the detection of circulating tumor DNA (ctDNA), in patients with resected stage II colon cancer, provides direct evidence of residual disease [17] . They showed that the sensitivity, specificity, positive predictive value, and negative predictive value of ctDNA for identifying patients with recurrence were 40.7%, 98.0%, 78.6%, and 90.2%, respectively [17] . Although ctDNA appears to be a superior biomarker for the detection of recurrence patients with curative intent than miRNAbased biomarkers, there are several issues with ctDNA-based biomarkers. First, several somatic mutations must be determined from the primary tumors by sequencing. Secondly, the volume of blood sample needed to extract adequate amount of ctDNA is significantly more than the blood required to measure the expression of miRNAs. Hence, miRNA-based biomarker such as miR-1290 is appealing as they require simpler detection methodology (qPCR) and robust preparation compared with ctDNA. While the limited sensitivity of miRNA-based biomarker must be improved using multiple-panel based approach or miRNA expression profiling in circulation, miRNA-based biomarkers are promising for prediction of recurrence in curative CRC patients. Despite serum expression of miR-1290 appears to be a promising biomarker for diagnosis of CRC and prediction of early recurrence and poor prognosis, the data shown in the current study have some limitations. Despite Peduzzi et al. [18] recommended a minimum number of variables required for an optimal multivariate analysis, our study included several variables in the multivariate analysis that we identified to be statistically significant in the univariate analysis. Our sample size could have been the contributing factor for these unusual findings. Considering that our study was conducted in a retrospective nature, we believe that future prospective studies with a large cohort numbers are required to clarify the usefulness of miR-1290 as a novel biomarker in CRC. In addition, we used different cut-off values for serum miR-1290 in different cohorts for diagnosis, prognosis, and recurrence. Defining the clear cut-off values for circulating miRNA biomarkers have been notoriously difficult for several reasons. First, CRC itself is a heterogeneous disease and the expression of miRNAs varying significantly within tumor population. Secondly, the lack of consensus on suitable small RNA reference genes to quantify circulating miRNA levels makes establishment of global cut-off value difficult. Thirdly, some miRNAs are highly expressed in the blood cells, and levels of circulating miRNAs can be significantly altered by hemolysis. Therefore, the standardization of protocols and methodologies, including sample storage, RNA extraction, and quantification of circulating miRNAs, are necessary to improve the biomarker potential of miRNAs.
We conclude that miR-1290 is a powerful and promising, serum-based non-invasive biomarker for the early detection and prognosis of colorectal neoplasia.
acknowledgements
We would like to express our gratitude to Mrs Chihiro Hibi for excellent technical assistance.
funding
This work was supported in part by Grants-in-Aid for Scientific Research (Nos. 26293301, 24591972, 15K10134, 25462018) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. This study was also supported by Grant aid for cancer research from Takeda Science Foundation, Japan. disclosure
